secwatch.observer — SEC 8-K summary
======================================

Issuer:     LogicBio Therapeutics, Inc. (—)
CIK:        0001664106
Form:       8-K
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0001104659-22-119520
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alexion completes acquisition of LogicBio for $2.07/share; shares to be delisted
--------------------------------------------------------------------------------

- Tender offer closed with 26.95M shares (81.76%) validly tendered; Merger completed under DGCL Section 251(h).
- Each share converted into $2.07 cash, less withholding; options and warrants cancelled per Merger Agreement.
- All prior board members and executive officers ceased; new directors and officers from Purchaser took over.
- Loan and Security Agreement with Oxford Finance terminated and fully repaid upon closing.
- LogicBio requested Nasdaq delisting and intends to file Form 15 to suspend SEC reporting obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/0001104659-22-119520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664106/000110465922119520/tm2230653d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-119520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer